Background: To confirm the treatment effects of concurrent cetuximab plus docetaxel observed in Radiation Therapy Oncology Group (RTOG) 0234 and single out the effect of cetuximab, we designed RTOG 1216, a randomized phase II/III study, which uses an intermediate end point to select the best regimen for definitive testing of survival benefit. Methods: In phase II, the best regimen should demonstrate statistically significant efficacy against the control with predefined advantage over the competing arm regarding disease-free survival (DFS). We evaluate operating characteristics of the randomized II/III group sequential design through simulations and numerical integrations under the null and various alternative hypotheses. Results: Results show the randomized II/III design yields substantial savings on sample size and time with well-controlled type I and type II error rates. Conclusion: Overall, the proposed randomized II/III design has desirable properties that offer cost effectiveness, operational efficiency, and, most importantly, scientific innovation that can be considered for similar clinical research settings.
| INTRODUCTION
Approximately 50% of patients with head and neck cancer undergo primary surgery in the treatment of their malignancy. For patients with advanced locoregional disease with high-risk features, recurrence rates after surgery alone are high and, therefore, postoperative treatment strategies have been actively investigated for several decades. The Radiation Therapy Oncology Group (RTOG) 0234 enrolled 238 highrisk patients with head and neck cancer in a randomized phase II trial to examine the feasibility and safety of delivering postoperative radiation combined with cetuximab plus either weekly cisplatin or docetaxel chemotherapy. When disease-free survival (DFS) was compared to historical control (the RTOG 9501 chemoradiation arm) the hazard ratio (HR) was 0.76 for cetuximab-cisplatin versus control, whereas it was 0.69 for cetuximab-docetaxel versus control (P = .01). 1 Therefore, it is important to confirm the treatment effects for the docetaxel arm in a randomized trial with the same control arm, and single out the effect of cetuximab with an efficient development plan. A randomized II/III design offers as a good option for this study because a third concurrent docetaxel only arm is included and the arm with the best efficacy, regarding DFS if demonstrated, will be chosen to test for the survival benefit in a timely manner. Randomized phase II/III designs, including studies with multiple experimental arms, have been used in selected oncology trials (Korn et al 2 ). Advantages of this approach include savings on sample size and overall duration of the treatment evaluation process. 3 In many cases, the same endpoint is used for treatment selection in phase II trials and comparison of efficacy in phase III trials. [4] [5] [6] [7] In practice, phase II decisions are often based on the intermediate end points, like response and progressionfree survival (PFS). Thus, end points in phase II and III components are likely different in terms of types of measures or definitions. For example, Korn et al 2 described the study design for CALGB-80802, which was assessing if doxorubicin plus sorafenib is superior to sorafenib alone in advanced liver cancer. The phase II component involved a comparison of PFS based on the first 170 patients (it targeted, a PFS HR of 0.67 with 90% power). The phase III component targets an overall survival (OS) HR of 0.73 with 480 patients. To date, Hunsberger et al, 3 Todd and Stallard, 8 and Royston et al 9 proposed phase II/III designs with a change of these survival end points from phase II to III. None of these can be applied directly to RTOG 1216. For example, Hunsberger et al 3 explored 2-arm designs without treatment selection using PFS and OS in each phase, and suggested to design the phase II study separately based on its own type I error rate and power. To avoid accruing excess patients to a potentially negative phase II trial, they also recommended accrual suspension during the follow-up in phase II. Todd and Stallard 8 considered the case with more than 2 arms.
They derived one stopping boundary for treatment selection and interim comparisons. 10 The arm with the largest treatment effect on an early end point is selected at the first interim analysis without confirming statistical significance. However, statistical significance is a requirement for standalone phase II trials to go to phase III. Royston et al 9 studied
2-stage only procedures using PFS and OS. More than 1 arm can be chosen from stage 1 without distinguishing their efficacy. Interim efficacy or futility analyses are not considered for either stage. There are also additional technical issues to consider in the design of RTOG 1216. Bauer and Posch 11 pointed out that because the 2 outcomes from the same patient are likely to be dependent, 12 thus, the type I error rate for the phase II/III design could be inflated. Moreover, when comparing more than 1 experimental arm to the control group, we need to adjust for the multiple comparisons in phase II in addition to controlling for the overall error rate for the phase II/III design. We can use the Dunnett 13 test and the Bonferroni method, 14 etc, to protect the error rates in phase II. The RTOG 1216 is designed to answer study specific questions, thus, it is novel in several aspects: treatment selection is performed in a manner similar to those in usual phase II trials designed with predefined error rate and power and allows only 1 arm to be carried to the next phase. The Go and No-Go decision is made based on: (1) statistically significant efficacy results on an early end point -DFS; and (2) if both arms are statistically significant, we expect better treatment effects over the competing arm for the winner to continue to phase III. We build in separate interim efficacy and futility monitoring rules for each phase.
| MATERIALS AND METHODS
In many randomized phase II oncology trials, we use DFS or PFS as the primary end point. This is typically defined as time to disease progression or death. Then, for the phase III comparison, we consider OS, which includes death due to any cause. In general, there are multiple candidate therapies like the setting in this article. The decision regarding experimental arm selection during phase II is made primarily using results from DFS. For example, in phase II, we would like to compare the treatment effects between each of the new regimens (arm 2: radiotherapy [RT] + chemotherapy B vs arm 3: RT + chemotherapy B + agent) and the standard arm (arm 1: RT + chemotherapy A) in terms of DFS and select the arm with better efficacy for the phase III testing. For RTOG 1216, chemotherapy A is cisplatin, chemotherapy B is docetaxel, and the agent is cetuximab (more details are in the Results section).
Regarding the multiplicity issue in the phase II component, we considered a comparison-specific type I error rate and we evaluate the overall alpha for all comparisons through either simulations or theoretical calculations. Group sequential methodologies ( denote the log of HR between each of the treatment arm and control. In phase II, the overall null hypothesis is H + δ > 0 (iv). δ is the increase in effect size due to cetuximab (eg, the expected HRs are 0.65 and 0.47 for arms 1 and 2.). The power of the study is the probability that arm 2 is selected and the null hypothesis is rejected in favor of a positive treatment difference (θ OS 2 ) under the alternative hypothesis. 8 To evaluate the design performance, we also consider other configurations. A decision rule based on each of these scenarios is formulated, as shown in Table 1 , and we investigate the design properties for each case, these include (i) θ Tables 2 and 3 ). In comparison to the method of Stallard and Todd, 6 an early end point of DFS is used here for treatment selection. One distinction from the method of Todd and Stallard 8 is that one or both of the experimental arms must improve DFS statistically significantly over the control. If both experimental arms show DFS improvement over control, the winning arm must ultimately demonstrate a 5% advantage over its counterpart. The 5% is chosen to reflect physician's expectation of minimal clinically meaningful difference. Otherwise, an arm is preferred due to less overall toxicity and cost, etc. Thus, being the most effective arm with only minimal improvement over the competing options does not satisfy the selection criteria we use in RTOG 1216. Of course, we also need to consider quality of life (QOL) and toxicities for arm selection, as explained in the Discussion section.
Once an arm is chosen in phase II, we can resume accrual and continue to the phase III. Patients in the selected arm from phase II will be included in the phase III analysis. The phase III null and alternative hypotheses are are H . Here, we broaden the usual definitions of error rate and power in standalone phase II and III trials to account for the hybrid nature of the randomized II/III design. According to the phase II decision rules and the phase III hypothesis, the overall error rate is the probability of an arm being chosen using DFS in phase II and then the null hypothesis is rejected again based on OS in phase III. Detailed definitions and expressions of these error rates are in Appendix B.
There are 2 methods to evaluate the performance of the design: numerical integrations and simulations. We will show how to control the type I error rates using the first method in each phase and in the overall II/III design based on theoretical results for the design of RTOG 1216. We first conducted Monte Carlo simulations to investigate the operating characteristics of this type of design and estimate the likely correlations among test statistics in each phase and the change of the overall error rates α II=III from the unadjusted, typical phase III α III of 0.025 and 0.05. We use the statistical software R 21 for all simulations and the CRAN library cubature 22 for the numerical integrations. 
| RESULTS
To see the overall error rates for the randomized II/III design relative to the phase III levels of 0.025 and 0.05, we have conducted simulations with 10 4 runs using parameters, as specified in Appendix C. In Tables 2 and 3 , we present the probabilities of making a Go decision at the phase II final analysis, and the observed type I error rates/powers for the whole trial, as defined in (A1) in the Appendix. For each combination of treatment effects (eg, no difference in either arm, only 1 arm is effective, or both arms are effective, etc, as in Table 1 ), the upper/lower rows are results for 80%/90% power and each cell shows rejection probabilities for the phase II and the overall II/III trial. As can be seen in Table 2 , we have included 8 combinations of HRs, each representing different treatment effects on DFS and OS by arm. The correlations are for between provisional DFS (or progression) and OS based on the bivariate exponential distributions.
Under the global null hypothesis (combination 1), there is 24% probability to continue to phase III if the correlation is 0.5, it is similar in the same rows in Table 3 . The probability is 91%/96% (combination 6) under each power when the 2 experimental arms are equally effective. With this design, we have an overall error rate of 0.02/0.02 (Table 2 ) and 0.042/0.037 (Table 3 ) as compared to the phase III design levels of 0.025 and 0.05 for each power. Notice that when the correlation is 1.0, the overall error rates are 0.0234/0.0274 under the null in Table 2 , the latter is slightly inflated numerically. These overall error rates are 0.054/0.055 for the same cases in Table 3 . This is less of a concern because the correlation between the 2 endpoints is usually <1.0. Results are similar with 10 5 simulations.
Therefore, the error rates are well controlled for the phase II and the II/III designs. When the 2 experimental arms are equally effective (combination 6), the overall study power would be 78%-79%/90% with the same correlation (0.5) in both Tables 2  and 3 . So when only arm 3 is effective (combination 3), 79%/88% of the trials will continue to phase III. Under the alternative hypothesis (combination 8) and each design power, the observed study power for the overall trial is 95%/98% in both Tables 2 and 3 . The statistical power for other combinations of treatment effects are in Tables 2 and  3 . These show the performance of the design if only DFS is improved (combinations 2 and 4), only one arm is statistically significant for both end points (combinations 3 and 5) or if the treatment is slightly less effective for OS in arm 2 (combination 7). Overall, the statistical power is satisfactory under the alternative hypothesis. Please note that the power for each of the comparisons in phase II and phase III alone is 80% per the separate design.
In phase II, when the correlation decreases from 1 to 0.25 between the 2 end points, the correlations between the test statistics are also reduced from 0.8 to 0.5, on average, within each arm and 0.4 to 0.25, on average, between the 2 experimental arms in Tables 2 and 3 under the null and each power. This builds the basis for the numerical integrations and simulations in the design of RTOG 1216. In addition, when the correlation decreases, the overall error rate and the statistical power become lower in general but remain satisfactory for both Tables 2 and 3. For completeness, Supporting Tables S1 and S2 show the percentage of rejections for each of the decision rules in phase II and the overall II/III trial for combinations 1 and 6. The RTOG 1216 is a randomized phase II/III trial of surgery and postoperative radiation delivered with concurrent cisplatin versus docetaxel versus docetaxel and cetuximab for high-risk squamous cell cancer of the head and neck. 1 The goal of the phase II component is to select the better experimental arm to improve DFS over the control arm of cisplatin plus radiation. In addition, this design aims to single out the effect of cetuximab. When the design concept was reviewed, we evaluated the operating characteristics through simulations using asymptotic joint distributions among the log-rank tests of DFS and OS. This is different from the 2 methods we consider in this article. Here, we directly simulated survival times based on bivariate exponential distributions for provisional DFS and OS and carried out log-rank tests at each stage, as described in the Methods section. The schema and detailed design parameters for RTOG 1216 are provided in Appendix D. The correlations among the test statistics for numerical integrations are based on the estimated averages over all simulations unlike the assumed values in the protocol. Under the null in phase II, for a correlation of 0.5 and estimated test correlations of about 0.45 and 0.23 among DFS, OS within each arm, and with the other arm, the probability of rejecting the null hypothesis is 9% and 9.7%. If only arm 2 or 3 is statistically significant, it is 4.4% and 1.5% for scenarios 4 and 5. When the 2 experimental arms are equally effective, these are 13.6%, 13.8%, 44.7%, and 16.9% based on 10 4 simulations. When only arm 3 is statistically significant for DFS, the probabilities are 0.9%, 62%, 4.2%, and 9.1%. The overall error rate is 0.027 from these simulations. Under the alternative hypothesis, the power is 94%, 80%, and 86% in phase II, III, and II/III. We can also successfully design these II/III trials and maintain error rates for phase II, III, and the overall study directly through numerical integrations without the complicated simulations, details can be found in Appendix B.
According to A3 and A4 in the Appendix, the expected sample sizes for RTOG 1216 are 254 and 449 under each hypothesis. The expected trial durations are 4.5 and 7 years, respectively. However, if we run the 3 arm phase II studies, and then a separate phase III study, it will take at least 12 years (if the transition from II to III takes about 3 years) and 588 patients. If we run 2 phase II studies sequentially, then the phase III trial, the total study duration will be at least 18 years with a sample size of 768 patients.
| DISCUSSION
The proposed RTOG 1216 design yields savings on sample size and time with well-controlled type I and type II error rates. Our design considers an early end point and it has clearly defined phase II and phase III type I and II error rates that are similar to those in separate trials. In addition, many of the recently proposed designs would pick the arm with the largest observed treatment effect regardless of the actual difference relative to other competing arms. This selection method does not guarantee it is statistically significantly better than the control. These designs cannot answer the questions we posed in RTOG 1216, in which we would like to know if both experimental arms are better than the cisplatin arm, and if so, is cetuximab providing any additional benefit. Unlike the 2-stage procedures, according to our design, we are able to monitor for early efficacy and futility in each component. In addition, the phase II portion allows sufficient follow-up with or without accrual suspension for time to event data and, thus, protects statistical power for the phase II efficacy testing.
This design is flexible and can certainly be extended to cases in which there are multiple agents to be added to the same or different backbone regimens one at a time or through other combinations, for example, having an increasing number of agents. We can develop decision rules for selecting 1 or multiple arms with design treatment differences among these candidate arms and against the control. The estimation of the correlation between PFS and OS in clinical trials is critical for these designs. A recent proposal in Li and Zhang 23 (2015) considered the more flexible Weibull distribution.
As mentioned in the Methods section, QOL and toxicity outcomes are also important in selecting the best arm. 1 In RTOG 1216, we will also assess grades 3 to 5 side effects and QOL among the 3 arms and identify if there is a statistically significant difference. If the cetuximab arm is not at least 5% better than arm 2 when both are statistically significant and the toxicities are similar, we will consider QOL differences. Otherwise, if arm 3 is more toxic than arm 2 regarding grade 3 to 5 side effects, including mucositis, dysphagia, dermatitis, etc, then we will choose arm 2 as the winner. For scenario 5 in Table 1 , if arm 3 also causes substantially increased toxicities, we will consider very carefully (including QOL) in selecting the preferred arm for phase III testing. One potential drawback of the proposed design is that the overall planning time could be longer for these randomized II/III designs, however, for the case of RTOG 1216, from concept review to study preactivation, it took 299 days meeting the National Cancer Institute (NCI) OEWG deadline for single-phase III trials. With more emerging choices for early efficacy, such as tumor size as measured by imaging, we can also utilize different end points (continuous and binary) in the phase II component. One recent successful example of a phase II/III design is a combination chemotherapy regimen consisting of oxaliplatin, irinotecan, fluorouracil, and leucovorin (FOLFIRINOX) versus gemcitabine for metastatic pancreatic cancer. 2, 24 This trial considered the response rate among the first 44 patient on the experimental arm and both the response rate and the OS benefits were confirmed in each phase. Overall, the proposed randomized II/III design has desirable properties, which offer cost-effectiveness, operational efficiency, and, most importantly, scientific innovation that may prove valuable to consider for similar clinical research settings.
APPENDIX
A: The distributions of the interim statistics are as follows: Let θ denote the measure of the difference of efficacy between one of the experimental arms and the control. In oncology trials, this is usually log-HRs (for the time to event end points like DFS and OS). We want to test the null hypothesis H 0 : θ = 0 versus the 1-sided alternative θ > 0, indicating the experimental arm is superior to the control.
We plan to conduct a total of J analyses and letθ j be the estimate of θ based on a log-rank test at analysis j. So the interim Z statistics have an asymptotic multivariate joint normal distribution 25 :θ j $ Nðθ in phase III, if Z j > u j , then we stop and reject the null hypothesis. If, however, Z j < l j , we recommend to stop and reject the alternative hypothesis. Note that we are monitoring 1 of the 2 endpoints alone in each phase, so the stopping boundaries can be derived using comparison-specific error rates.
B: As discussed earlier that the standardized log-rank test statistics (normalized treatment difference): Y DFSð2 vs 1Þ , Y DFSð3 vs 1Þ in phase II and Z OSð2 vs 1Þ , Z OSð3 vs 1Þ in phase III are correlated, so the joint distribution g 1 of, for example, y DFSð2 vs 1Þ , y DFSð3 vs 1Þ and z OSð2 vs 1Þ are asymptotically three dimensional normal. In phase II, the total error rate accounting for multiple comparisons is: 
Then the total error rate of the II/III design according to the phase II, III final analyses is: . Numerical integrations of the 4 multiple integrals quantifies the decision rules under the global null and specific alternative hypotheses. To do this we either set the expected error rate α II=III , for the randomized II/III trial then derive the phase III critical value/alpha (α III ) or use the preset phase III critical value/alpha to obtain the overall error rates through numerical integrations using the theoretical results in A1 and A2 above. For example, in phase II (Supporting Figure S1 , panel 1), when α II total = 0.15, the probabilities for choosing arm 2 is 12% (include 2.7% for scenario 4 in Table 1 ) and 10% (include 0.8% for scenario 5 in Table 1 ) for arm 3. Panel 2 in Supporting Figure S1 shows the phase III final alphas if we expect the overall error rates α II=III = 0.01, 0.025, and 0.05 for the whole study with given design correlations among test statistics. For example, we need a phase III final alpha of 0.035 to obtain an overall error rate of 0.025 (ρ = 0.6 between DFS and OS tests in phase II). When the correlation increases, the phase III design alphas decrease. We can see that the overall alpha is less than the design level in phase III for these cases. On the other hand, we can also tell how much the error rate changes given a phase III design type I error rate α III (panel 3). If we want to control the conditional probabilities of rejecting the null hypothesis given that any arm is chosen to go to the phase III (9.6% from simulations) α II=III =α II total , we can find the phase III design alpha and overall error rate using similar algorithms (panel 4). For a design similar to that of RTOG 1216 with correlations of 0.4 and 0.2 among test statistics within and between arms at final analyses, the overall adjusted error rate after three interim analyses for the II/III design is 0.034 using numerical integration. Alternatively, we can verify these results through simulations with various parameter combinations, as presented in Tables 2 and 3 .
The expected sample sizes and trial time of the phase II and III components are calculated as in a typical group sequential design. However, the expected sample size for the II/III design is 
where n 1 is the sample size for one arm in phase II and n 2 is the total sample size for phase III. The expected trial time is: Table S1 ) and correlation of 0.5, the probability that only one arm is better than the control is about 18%-19%, this is similar in both Tables 2 and 3 . Under the null for scenario 4 in Table 1 , the probability is 3.7%/4.4% under each power but it is 1.3%/1% in Tables 2  and 3 according to scenario 5 for DFS at 1.5 years. Therefore, we see that when there is no treatment effect, the falsepositive rate is more likely due to one of the arms being false-positive. When the 2 experimental arms are equally effective (Supporting Table S2 ), for scenarios 2 and 3 together, the probability is about 25%/17%. For scenario 4, the probability is 51%/63% but it is 14%/17% in each table according to scenario 5. For this case, it is more likely that arm 2 will be selected if both are equally effective. However, under the alternative hypothesis (not shown in Supporting  Tables S1 or S2) , these are 0.8%, 21.8%, 32%, and 44% with 80% power. So the probability that arm 3 is selected is much higher now. For the overall II/III trial with each power, the probabilities for scenarios 2 and 3, 4, and 5 are 1.6%/1.53%, 0.31%/0.36%, and 0.10%/0.08% in Supporting Table S1 and these are 3.31%/2.85%, 0.63%/0.68%, and 0.21%/0.16% in Supporting Table S2 under the null. When the 2 experimental arms are equally effective, the probabilities for scenarios 2 and 3, 4, and 5 are 22.04%/15.72%, 44.14%/58.16%, and 11.87%/15.76% in Supporting Table S1 and these are 22.29%/15.79%, 44.47%/58.40%, and 11.96%/15.83% in Supporting Table S2 . The total for each set of these, for example, in Supporting Table S2 , equals 0.0415/0.0369 and 0.79/0.90, which are the overall error rates and power in Table 3 (combinations 1 and 6). Under the alternative hypothesis, these are 0.78%, 20.9%, 30.7%, and 42.2% with 80% power. The patterns regarding change of probability for picking the winner for each scenario from the null to the alternative hypothesis are similar to those in phase II, as described earlier. NOTE: If the trial proceeds to the phase III component, arm 2 or arm 3 will be chosen as the experimental arm. Patients accrued in the phase II component of the trial will complete the treatment to which they are randomized (arm 1, 2, or 3) and will be followed as specified in the protocol.
In RTOG 1216, we assume the 3-year DFS is 35% based on RTOG 0234, with 1-sided type I error rate of 15% and 80% power and a HR of 0.6, we need 60 analyzable patients per arm in the phase II study. The accrual will take 2.2 years and total study duration of 3.5 years. We conduct one interim futility analysis when there is 50% of the required information in phase II. We will suspend the study accrual during the follow-up phase and compare the arms using DFS, while considering effects on QOL, toxicities, etc. Table 1 shows the decision rule for selecting a better arm, in particular, if both arms are statistically significant and the cetuximab arm is at least 5% better in terms of DFS, then it will go to phase III. The dropped arm will not be included in the phase III final analysis. For the design of phase III, the 120 patients from phase II will be included. We assume that the 3-year OS is 45% from data of RTOG 9501 and 0234.
